Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Revenue (2016 - 2025)

Guided Therapeutics' Revenue history spans 16 years, with the latest figure at $590000.0 for Q4 2025.

  • On a quarterly basis, Revenue rose 58900.0% to $590000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $767000.0, a 10857.14% increase, with the full-year FY2025 number at $767000.0, up 10857.14% from a year prior.
  • Revenue hit $590000.0 in Q4 2025 for Guided Therapeutics, up from $60000.0 in the prior quarter.
  • Over the last five years, Revenue for GTHP hit a ceiling of $590000.0 in Q4 2025 and a floor of $1000.0 in Q4 2024.
  • Historically, Revenue has averaged $69000.0 across 5 years, with a median of $20500.0 in 2021.
  • Biggest five-year swings in Revenue: crashed 96.88% in 2024 and later surged 58900.0% in 2025.
  • Tracing GTHP's Revenue over 5 years: stood at $60000.0 in 2021, then plummeted by 95.0% to $3000.0 in 2022, then surged by 966.67% to $32000.0 in 2023, then crashed by 96.88% to $1000.0 in 2024, then surged by 58900.0% to $590000.0 in 2025.
  • Business Quant data shows Revenue for GTHP at $590000.0 in Q4 2025, $60000.0 in Q3 2025, and $117000.0 in Q2 2025.